This inventor holds 2 USPTO granted patents. Top assignees: Massachusetts Institute of Technology, The General Hospital Corporation. Active years: 1998-1999.
Location History:
- Orsay, FR (1998)
- Chalfont, PA (US) (1999)
Company Filing History:
2 out of 8,576 
2 out of 3,070 
Years Active: 1998-1999
Title: Keith Bupp: Innovator in Amyloid Precursor-Like Proteins
Introduction
Keith Bupp is a notable inventor based in Orsay, France. He has made significant contributions to the field of biomedical research, particularly in the study of amyloid precursor-like proteins. With a total of 2 patents, his work has implications for understanding and potentially treating Alzheimer's disease.
Latest Patents
Bupp's latest patents focus on isolated amyloid precursor-like proteins (APLPs) and their applications. The first patent, titled "Amyloid precursor-like protein and uses thereof," describes isolated APLPs, nucleotide sequences that code for these proteins, and antibodies that can detect APLPs in biological specimens. This invention highlights the potential of APLP1 and APLP2 as candidate genes for late-onset familial Alzheimer's disease. The second patent, "Nucleic acid encoding amyloid precursor-like protein and uses thereof," shares similar themes, emphasizing the importance of APLPs in medical diagnostics and research.
Career Highlights
Throughout his career, Keith Bupp has worked with prestigious organizations, including The General Hospital Corporation and the Massachusetts Institute of Technology. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Bupp has collaborated with notable colleagues such as Wilma Wasco and Margaret Magendantz. Their combined expertise has further advanced the understanding of amyloid precursor-like proteins and their relevance to Alzheimer's disease.
Conclusion
Keith Bupp's innovative work in the field of amyloid precursor-like proteins has the potential to impact Alzheimer's disease research significantly. His patents and collaborations reflect a commitment to advancing medical science and improving patient outcomes.